Xingfa Group (600141): Organic silicon weighs on performance and is optimistic about long-term development of phosphorus chemical leader

Xingfa Group (600141): Organic silicon weighs on performance and is optimistic about long-term development of 南京夜网 phosphorus chemical leader Performance summary: The company achieved operating income of 144 in the first three quarters of 2019. 5 ppm, an increase of ten years. 0%; net profit attributable to mother 3. 0 ppm, a reduction of 23…

[Dangers of intercourse before menstruation]_ Intercourse during menstruation _ Some kind of harm _ Physical injury _ Adverse effects

[Dangers of intercourse before menstruation]_ Intercourse during menstruation _ Some kind of harm _ Physical injury _ Adverse effects We all know that girls always have so many days in each month, which is quite special. During this time, girls’ bodies are actually in a relatively fragile period, so at this time, if they have…

[Effects of Stone Flowers]_Action_Benefits

[Effects of Stone Flowers]_Action_Benefits Stone flower is a plant with high medicinal value, which is good for conditioning people’s liver. Stone flower is also very common, and it is a very common medicinal material in Chinese medicine. First of all, Shihuacao is used in many heat relieving and detoxifying and hemostatic prescriptions. Stone flower grass…

Biological Stock (600201): Long-term growth opportunities under pressure due to epidemic performance

Biological Stock (600201): Long-term growth opportunities under pressure due to epidemic performance 2018 / 1Q19 return to net profit -13. 29% /-46. 46%, 杭州夜网 the performance is lower than expected Biological shares announced 2018 and 1Q19 results: 2018 revenue / net profit attributable to mother-0 per year. 23% /-13. 29% to 18. 97/7. 54 ppm,…

Wangfujing (600859) 2019 Interim Report Review: Olay Format Drives Northwest and Northeast Revenue Growth and Overall Profits Under Pressure

Wangfujing (600859) 2019 Interim Report Review: Olay Format Drives Northwest and Northeast Revenue Growth and Overall Profits Under Pressure Event: On August 31, 2019, Wangfujing released its 19-year interim report, and the company achieved operating income of 134 in the first half of 2019. 22 ppm, an increase of 1 per year. 69%; net profit…

East China Pharmaceutical (000963): Performance exceeded expectations and high growth in the pharmaceutical industry

East China Pharmaceutical (000963): Performance exceeded expectations and high growth in the pharmaceutical industry Event: The company released its 2018 annual report on the evening of April 18, and realized operating income of 306 in 2018. 63 ppm, an increase of 10 in ten years. 17%; realized net profit attributable to mother 22. 67 ppm,…